Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Oramed Pharmaceuticals Inc. - Common Stock
(NQ:
ORMP
)
3.430
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Oramed Pharmaceuticals Inc. - Common Stock
< Previous
1
2
3
4
Next >
Why Is Oramed (ORMP) Stock Down 75% Today?
↗
January 12, 2023
Oramed (ORMP) stock is falling hard Thursday after announcing a Phase 3 clinical trial of its diabetes treatment missed its primary endpoint.
Via
InvestorPlace
Dow Drops 150 Points; US Inflation Rate Slows In December
↗
January 12, 2023
U.S. stocks traded lower this morning, following the release of inflation data.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
January 12, 2023
Via
Benzinga
Why Akerna Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket
↗
January 12, 2023
Gainers Akerna Corp. (NASDAQ: KERN) rose 97.4% to $1.91 in pre-market trading after the company reported the sale of 365 Cannabis for $2.8 million.
Via
Benzinga
Looking Into Oramed Pharmaceuticals's Return On Capital Employed
↗
December 22, 2022
Via
Benzinga
Oramed Pharma Shares Fall After Additional Data From Oral Insulin Study
↗
November 17, 2022
Via
Benzinga
Oramed Pharmaceuticals' Oral COVID-19 Vaccine Candidate Shows Safety, Immunogenicity In Early Study
↗
October 07, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
↗
January 12, 2023
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday!
Via
InvestorPlace
Oramed Pharma Shares Sink After Diabetes Candidate Fails In Phase 3 Study
↗
January 12, 2023
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) announced top-line results from its Phase 3 trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26...
Via
Benzinga
Oramed Pharmaceuticals, Logitech International And Some Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
January 12, 2023
U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Jim Cramer Says Avoid This Stock: 'Too Expensive'
↗
January 05, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Blackline, Inc. (NASDAQ: BL) was an enterprise software company that was losing money.
Via
Benzinga
Li Auto, XPeng, Nio And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
↗
January 03, 2023
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
↗
September 13, 2022
Via
Benzinga
Oramed Oral Insulin Shows Evidence For NASH Treatment
↗
September 13, 2022
Oramed Pharmaceuticals Inc (NASDAQ: ORMP) announced Phase 2 results from its trial of its oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes (T2D) patients with...
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
↗
July 26, 2022
Via
Benzinga
Oramed Accomplishes 50 Percent Enrolment In Late-Stage Oral Insulin Study
↗
July 26, 2022
Oramed Pharmaceuticals (NASDAQ: ORMP) has enrolled over 50 percent of the planned 450 patients for its international multicenter Phase 3 ORA-D-013-2 trial of oral insulin capsule, ORMD-0801, for the...
Via
Benzinga
Short Volatility Alert: Oramed Pharmaceuticals Inc.
↗
July 21, 2022
On Wednesday, shares of Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) experienced volatile short activity. After the activity, the stock price went up +4.16% to $8.77. The overall sentiment for ORMP has...
Via
Benzinga
Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session
↗
July 12, 2022
Gainers
Via
Benzinga
Tesla, Twitter And 76 Biggest Movers From Friday
↗
July 11, 2022
Gainers Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board...
Via
Benzinga
Dow Rises 75 Points; Kura Sushi USA Shares Spike Higher
↗
July 08, 2022
U.S. stocks traded slightly higher toward the end of trading as investors digested the recent jobs report for the month of June.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
July 08, 2022
Via
Benzinga
Mosaic Tumbles Around 10%, Here's 71 Biggest Movers From Yesterday
↗
June 24, 2022
Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
June 03, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 18, 2022
↗
February 18, 2022
Upgrades Roth Capital upgraded the previous rating for Denbury Inc (NYSE:DEN) from Neutral to Buy. For the third quarter, Denbury had an EPS of $0.74, compared to year-ago...
Via
Benzinga
This Company Says Its Developing a COVID-19 Vaccine That Can be Taken Orally
↗
January 13, 2022
Photo by FRANK MERIÑO from Pexels This post contains sponsored advertising content. This content is for informational purposes only and not intended to be...
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
April 20, 2022
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new...
Via
Benzinga
52 Biggest Movers From Yesterday
↗
February 02, 2022
Gainers ION Geophysical Corporation (NYSE: IO) shares surged 29.8% to settle at $0.5969. Synaptogenix, Inc. (NASDAQ: SNPX) climbed 29.4% to close at $10.09. Synaptogenix...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
December 06, 2021
Gainers Adicet Bio (NASDAQ:ACET) stock increased by 37.85% to $13.51 during Monday's pre-market session. The market value of their outstanding shares is at $431.7...
Via
Benzinga
36 Stocks Moving In Tuesday's Mid-Day Session
↗
November 23, 2021
Gainers Pasithea Therapeutics Corp. (NASDAQ: KTTA) shares jumped 216.6% to $7.00 after the company announced its subsidiary Pasithea Clinics has been approved to provide...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
November 23, 2021
Gainers Pasithea Therapeutics (NASDAQ:KTTA) stock increased by 157.46% to $5.69 during Tuesday's pre-market session. The company's market cap stands at $75.1...
Via
Benzinga
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.